肝癌局部区域治疗与免疫治疗联合应用
局部区域治疗是肝细胞癌常用治疗手段,除直接消除肿瘤外可能产生全身免疫效应。随着免疫治疗应用于肝细胞癌,如何最佳联合局部区域治疗与免疫治疗受到关注。本文总结该领域已解答与未解答的问题,包括动物模型选择、肿瘤细胞死亡对免疫应答的影响、不同局部区域治疗观察到的免疫应答类型、首个联合免疫检查点阻断研究的结果,并讨论未来研究方向与介入放射学与肿瘤免疫学之间的差距。
要点
- 局部区域治疗可能通过免疫学「副作用」产生全身效应。
- 需确定最适合测试局部区域治疗联合免疫治疗的动物模型。
- 肿瘤细胞死亡如何影响免疫应答是待解答问题。
核心结论
- 局部区域治疗可能具有超越单纯肿瘤消除的全身效应,联合免疫治疗是肝细胞癌治疗的重要研究方向。
研究设计与样本
- 本文为综述,总结肝细胞癌局部区域治疗联合免疫治疗领域的已解答与未解答问题。
主要发现
- 动物研究和患者中已描述局部区域治疗后的免疫学「副作用」。
- 随着免疫治疗用于肝细胞癌,确定其与局部区域治疗最佳联合方式的兴趣日益增加。
- 本文汇总了动物模型选择、肿瘤细胞死亡对免疫应答的影响、不同局部区域治疗观察到的免疫应答类型以及首个联合免疫检查点阻断研究的结果等问题。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Locoregional therapies are commonly used to treat patients with hepatocellular carcinoma. It has been noted for many years that locoregional therapies may have additional systemic effects other than simple tumour elimination. Immunological "side effects" have been described in response to locoregional therapies in animal studies and in patients. With the advent of immunotherapy for hepatocellular carcinoma, there is increasing interest in determining the best way to combine immunotherapy with locoregional therapies. Herein, we provide a compact summary of answered and unanswered questions in the field, including: What animal model is best suited to test combined immune-locoregional treatments? How does tumour cell death affect immune responses? What type of immune responses have been observed in patients treated with different types of locoregional therapies? What can be surmised from the results of the first study testing the combination of locoregional therapy with immune checkpoint blockade? Finally, we discuss the outlook for this rapidly growing area of research, focussing on the issues which must be overcome to bridge the gap between interventional radiology and cancer immunology.
引用
- Greten TF, Mauda-Havakuk M, Heinrich B, et al. Combined locoregional-immunotherapy for liver cancer. J Hepatol. 2019. PMID: 30738077. doi:10.1016/j.jhep.2019.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。